MLTX vs. ENTA
MLTX (MoonLake Immunotherapeutics) and ENTA (Enanta Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, MLTX returned 16.38%/yr vs -22.50%/yr for ENTA. At a 0.13 correlation, their price movements are largely independent.
Performance
MLTX vs. ENTA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MLTX achieves a 68.13% return, which is significantly higher than ENTA's -15.22% return.
MLTX
- 1D
- 15.36%
- 1M
- 21.83%
- YTD
- 68.13%
- 6M
- 64.27%
- 1Y
- -49.06%
- 3Y*
- -5.04%
- 5Y*
- 16.38%
- 10Y*
- —
ENTA
- 1D
- 5.61%
- 1M
- -4.16%
- YTD
- -15.22%
- 6M
- -17.52%
- 1Y
- 86.21%
- 3Y*
- -15.60%
- 5Y*
- -22.50%
- 10Y*
- -4.99%
MLTX vs. ENTA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
MLTX MoonLake Immunotherapeutics | 68.13% | -75.66% | -10.33% | 475.14% | 6.17% | -13.02% | 11.91% |
ENTA Enanta Pharmaceuticals, Inc. | -15.22% | 174.26% | -38.89% | -79.77% | -37.79% | 77.62% | -3.24% |
Correlation
The correlation between MLTX and ENTA is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.22 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.24 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.15 |
Correlation (All Time) Calculated using the full available price history since Oct 20, 2020 | 0.13 |
The correlation between MLTX and ENTA shifts across timeframes, from 0.13 (all time) to 0.24 (3 years), reflecting how their relationship changes across market environments.
Fundamentals
MLTX:
$1.58B
ENTA:
$386.29M
MLTX:
-$3.90
ENTA:
-$2.67
MLTX:
6.22
ENTA:
3.35
MLTX:
$0.00
ENTA:
$69.21M
MLTX:
-$1.49M
ENTA:
$33.44M
MLTX:
-$179.84M
ENTA:
-$61.85M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MLTX vs. ENTA — Risk / Return Rank
MLTX
ENTA
MLTX vs. ENTA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for MoonLake Immunotherapeutics (MLTX) and Enanta Pharmaceuticals, Inc. (ENTA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MLTX | ENTA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.21 | ||
| Sortino ratioReturn per unit of downside risk | -1.40 | ||
| Omega ratioGain probability vs. loss probability | 1.25 | 1.31 | -0.06 |
| Calmar ratioReturn relative to maximum drawdown | -0.55 | 2.53 | -3.07 |
| Martin ratioReturn relative to average drawdown | -0.76 | 4.68 | -5.44 |
Loading charts...
Drawdowns
MLTX vs. ENTA - Drawdown Comparison
The maximum MLTX drawdown since its inception was -90.22%, smaller than the maximum ENTA drawdown of -96.63%. Use the drawdown chart below to compare losses from any high point for MLTX and ENTA.
Loading charts...
Drawdown Indicators
| MLTX | ENTA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -90.22% | -96.63% | +6.41% |
Max Drawdown (1Y)Largest decline over 1 year | -89.93% | -34.30% | -55.63% |
Max Drawdown (3Y)Largest decline over 3 years | -90.22% | -80.85% | -9.37% |
Max Drawdown (5Y)Largest decline over 5 years | -90.22% | -95.62% | +5.40% |
Max Drawdown (10Y)Largest decline over 10 years | — | -96.63% | — |
Current DrawdownCurrent decline from peak | -65.30% | -89.42% | +24.12% |
Average DrawdownAverage peak-to-trough decline | -29.48% | -49.33% | +19.85% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 64.55% | 18.48% | +46.07% |
Volatility
MLTX vs. ENTA - Volatility Comparison
MoonLake Immunotherapeutics (MLTX) has a higher volatility of 19.22% compared to Enanta Pharmaceuticals, Inc. (ENTA) at 16.79%. This indicates that MLTX's price experiences larger fluctuations and is considered to be riskier than ENTA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MLTX | ENTA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.22% | 16.79% | +2.43% |
Volatility (6M)Calculated over the trailing 6-month period | 55.52% | 36.33% | +19.19% |
Volatility (1Y)Calculated over the trailing 1-year period | 116.84% | 109.99% | +6.85% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 91.48% | 73.54% | +17.94% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 86.43% | 60.78% | +25.65% |
Dividends
MLTX vs. ENTA - Dividend Comparison
Neither MLTX nor ENTA has paid dividends to shareholders.
Financials
MLTX vs. ENTA - Financials Comparison
This section allows you to compare key financial metrics between MoonLake Immunotherapeutics and Enanta Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
MLTX and ENTA have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MLTX has higher volatility (19.22%) compared to ENTA (16.79%). In terms of maximum drawdown, MLTX dropped -90.22% vs ENTA's -96.63%.
ENTA currently has the higher Sharpe Ratio (0.79 vs -0.42), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MLTX and ENTA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer